Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 6767 | 2019 |
Cardiovascular and renal outcomes with empagliflozin in heart failure M Packer, SD Anker, J Butler, G Filippatos, SJ Pocock, P Carson, ... New England Journal of Medicine 383 (15), 1413-1424, 2020 | 4694 | 2020 |
Empagliflozin in heart failure with a preserved ejection fraction SD Anker, J Butler, G Filippatos, JP Ferreira, E Bocchi, M Böhm, ... New England Journal of Medicine 385 (16), 1451-1461, 2021 | 3836 | 2021 |
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 1960 | 2022 |
Sotagliflozin in patients with diabetes and recent worsening heart failure DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ... New England journal of medicine 384 (2), 117-128, 2021 | 1723 | 2021 |
Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1686 | 2012 |
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis S Verma, CH Wang, SH Li, AS Dumont, PWM Fedak, MV Badiwala, ... Circulation 106 (8), 913-919, 2002 | 1677 | 2002 |
Adipokines: molecular links between obesity and atheroslcerosis DCW Lau, B Dhillon, H Yan, PE Szmitko, S Verma American Journal of Physiology-Heart and Circulatory Physiology 288 (5 …, 2005 | 1480 | 2005 |
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein S Verma, SH Li, MV Badiwala, RD Weisel, PWM Fedak, RK Li, B Dhillon, ... Circulation 105 (16), 1890-1896, 2002 | 1285 | 2002 |
Low-dose methotrexate for the prevention of atherosclerotic events PM Ridker, BM Everett, A Pradhan, JG MacFadyen, DH Solomon, ... New England Journal of Medicine 380 (8), 752-762, 2019 | 1255 | 2019 |
New markers of inflammation and endothelial cell activation: Part I PE Szmitko, CH Wang, RD Weisel, JR De Almeida, TJ Anderson, ... Circulation 108 (16), 1917-1923, 2003 | 1185 | 2003 |
Fundamentals of endothelial function for the clinical cardiologist S Verma, TJ Anderson Circulation 105 (5), 546-549, 2002 | 1129 | 2002 |
Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction S Verma, SH Li, CH Wang, PWM Fedak, RK Li, RD Weisel, DAG Mickle Circulation 108 (6), 736-740, 2003 | 1080 | 2003 |
Clinical and pathophysiological implications of a bicuspid aortic valve PWM Fedak, S Verma, TE David, RL Leask, RD Weisel, J Butany Circulation 106 (8), 900-904, 2002 | 1023 | 2002 |
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review S Verma, JJV McMurray Diabetologia 61, 2108-2117, 2018 | 999 | 2018 |
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. SR Mehta, S Yusuf, R Díaz, J Zhu, P Pais, D Xavier, E Paolasso, R Ahmed, ... Jama 293 (4), 437-446, 2005 | 907 | 2005 |
Endothelial function testing as a biomarker of vascular disease S Verma, MR Buchanan, TJ Anderson Circulation 108 (17), 2054-2059, 2003 | 893 | 2003 |
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle CH Wang, SH Li, RD Weisel, PWM Fedak, AS Dumont, P Szmitko, RK Li, ... Circulation 107 (13), 1783-1790, 2003 | 890 | 2003 |
Endothelial cell control of thrombosis JW Yau, H Teoh, S Verma BMC cardiovascular disorders 15, 1-11, 2015 | 847 | 2015 |
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and … S Verma, MA Kuliszewski, SH Li, PE Szmitko, L Zucco, CH Wang, ... Circulation 109 (17), 2058-2067, 2004 | 816 | 2004 |